Plaque Psoriasis
Plaque psoriasis is a chronic skin condition characterized by red, scaly patches that can be itchy and painful. It occurs when the immune system mistakenly attacks healthy skin cells, leading to rapid skin cell growth.
Plaque Psoriasis: Bimekizumab Study
We are exploring how bimekizumab affects gene expression in people with moderate to severe plaque psoriasis. The study also looks at the safety of this treatment for those with or without psoriatic arthritis.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Psoriatic Arthritis
Psoriatic arthritis is a type of inflammatory arthritis that affects some people with psoriasis. It causes joint pain, stiffness, and swelling, and can lead to joint damage if not treated.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you at least 18 years old?
- Do you have plaque psoriasis diagnosed for at least 6 months?
- Are you currently pregnant or breastfeeding?
- Is your body weight less than 120 kg?
- Do you have a documented diagnosis of adult-onset psoriatic arthritis?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Charite Universitaetsmedizin Berlin KöR
#40515; Dermatologie & Allergologie
Berlin, Germany
Goethe University Frankfurt
#40287; Dermatology
Frankfurt am Main, Germany
Medical Center - University Of Freiburg
#40072; Klinik für Dermatologie und Allergologie
Freiburg, Germany
Sponsor: UCB Biopharma
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.